Should an 82‑year‑old patient be prescribed Repatha (evolocumab)?

Should an 82-Year-Old Take Repatha?

Yes, an 82-year-old patient should be prescribed Repatha (evolocumab) if they have atherosclerotic cardiovascular disease (ASCVD) and elevated LDL-C despite maximally tolerated statin therapy, as older patients derive at least equal—and often greater—absolute cardiovascular benefit compared to younger patients.

Evidence Supporting Use in Older Adults

The FDA label explicitly addresses geriatric use: 41% of patients in controlled trials were ≥65 years and 8% were ≥75 years, with no overall differences in safety or effectiveness observed between elderly and younger patients 1. This is critical—the drug was extensively studied in this age group and proven safe.

More compellingly, the most recent 2025 FOURIER long-term extension study specifically analyzed patients ≥75 years (median age 77) over a median 7.1 years of follow-up. Early initiation of evolocumab reduced cardiovascular events with a hazard ratio of 0.79 (95% CI: 0.64-0.97) in older patients versus 0.86 (95% CI: 0.80-0.92) in younger patients 2. The absolute risk reduction was actually higher in older patients at 5.4% versus 2.3% in younger patients, yielding a number needed to treat of only 19 in older adults compared to 44 in younger patients 2.

Clinical Decision Algorithm

Step 1: Confirm Indication

Does the patient have:

• ASCVD (prior MI, stroke, stable angina, PAD, or coronary revascularization), OR
• Primary hyperlipidemia with high risk (familial hypercholesterolemia)

Step 2: Assess LDL-C on Current Therapy

Is LDL-C elevated despite maximally tolerated statin ± ezetimibe?

• For ASCVD patients: The 2022 ACC guidelines support PCSK9 inhibitors as adjunct therapy when LDL-C remains elevated on statin therapy 3
• For primary prevention without ASCVD: ESC/EAS guidelines recommend LDL-C >4.5 mmol/L (>180 mg/dL) as threshold, or >3.6 mmol/L (>140 mg/dL) with additional risk factors 4

Step 3: Verify No Contraindications

• History of hypersensitivity to evolocumab (only absolute contraindication) 1
• No dose adjustment needed for renal impairment or mild-moderate hepatic impairment 1

Step 4: Prescribe Appropriate Dosing

• 140 mg subcutaneously every 2 weeks, OR
• 420 mg subcutaneously once monthly 3, 1

Both regimens produce equivalent LDL-C reductions of approximately 56-64% 3.

Safety Profile in Older Adults

The safety data are reassuring. In the cardiovascular outcomes trial, common adverse reactions (>5%) included diabetes mellitus (8.8% vs 8.2% placebo), nasopharyngitis (7.8% vs 7.4%), and upper respiratory infections (5.1% vs 4.8%)—essentially no difference from placebo 1.

Injection site reactions occurred in only 3.2% of evolocumab patients versus 3.0% on placebo 1. Discontinuation due to adverse events was low at 2.2% for evolocumab versus 1% for placebo 1.

Critically, the 2025 long-term study in older patients found that annualized incidence rates of safety events appeared similar across treatment arms in both age groups, with no significant safety concerns over 7+ years of follow-up 2.

Cardiovascular Outcomes Evidence

The FOURIER trial demonstrated that evolocumab reduced the primary composite endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) with a hazard ratio of 0.85 (95% CI: 0.79-0.92, P<0.001) 5. The key secondary endpoint (CV death, MI, or stroke) showed even greater benefit with HR 0.80 (95% CI: 0.73-0.88, P<0.001) 5.

These benefits translate directly to mortality and morbidity reduction—the outcomes that matter most. The 2025 VESALIUS-CV trial further confirmed that even in patients without prior MI or stroke, evolocumab reduced 3-point MACE by 25% (HR 0.75,95% CI: 0.65-0.86, P<0.001) 6.

Common Pitfalls to Avoid

1. Don't withhold based on age alone: The evidence shows older patients benefit more in absolute terms, not less 2

2. Don't delay initiation: The 2025 FOURIER-OLE data show benefits accrue over time—earlier is better for cumulative risk reduction 2

3. Don't assume statin intolerance precludes use: Evolocumab works independently of statins through PCSK9 inhibition and can be used as monotherapy if needed 3

4. Don't forget to check adherence first: Before adding evolocumab, confirm the patient is actually taking their current statin therapy 4

5. Don't worry about cognitive effects: Multiple trials (FOURIER, EBBINGHAUS) found no evidence of increased cognitive adverse effects even with very low LDL-C levels 3

Practical Considerations

The medication requires subcutaneous injection every 2 weeks or monthly, which some older patients may find challenging. However, the prefilled autoinjector (SureClick) is designed for self-administration 1. Consider caregiver assistance if manual dexterity is limited.

Cost and prior authorization requirements are real barriers 3, but should not prevent prescribing when clinically indicated—the cardiovascular benefit in this high-risk population is substantial and evidence-based.

The bottom line: Age 82 is not a contraindication to Repatha—it may actually be an indication for more aggressive therapy given the higher absolute benefit observed in older adults with ASCVD.